Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.41 |
| ▸ | HTR2C | P28335 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069648 | 0.86 | ADRA2A (0.42) | GAATSHRTTRADRA2AADRA2B | |
| SCHEMBL16341129 | 0.85 | GAA (0.48) | GAATSHRADRA2AADRA2BADRA2C | |
| SCHEMBL2523426 | 0.85 | NPC1 (0.52) | GAATSHRTTRADRA2AADRA2B | |
| SCHEMBL13922744 | 0.85 | CSNK2A1 (0.47) | GAATSHRADRA2AADRA2BADRA2C | |
| SCHEMBL11410920 | 0.83 | GAA (0.47) | GAATSHRADRA2AADRA2BADRA2C | |
| SCHEMBL4523312 | 0.81 | GAA (0.41) | GAATSHRADRA2AADRA2BADRA2C | |
| SCHEMBL3455041 | 0.81 | GAA (0.44) | GAATSHRADRA2AADRA2BADRA2C | |
| SCHEMBL9545504 | 0.80 | TSHR (0.61) | GAATSHRADRA2AADRA2BADRA2C | |
| SCHEMBL4879810 | 0.80 | ALDH1A1 (0.56) | GAATTRSMN1; SMN2ALDH1A1MEN1 | |
| Alclofenac SCHEMBL25703 | 0.80 | PPARD (0.62) | GAATSHRSMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486992-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2013-07-16 | — | — | US | disclosed |
| US-8268881-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2012-09-18 | — | — | US | disclosed |
| CN-101268046-B | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER | 2012-07-25 | — | — | CN | disclosed |
| US-20110251164-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2011-10-13 | — | — | US | disclosed |
| US-7772223-B2 | 5-Methyl-5-(3-phenoxyazetidin-1-yl)-2,2-diphenylhexanamide, used for the treatment of respiratory system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis and emphysema | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-02-04 | — | — | US | disclosed |
| EP-1928821-B1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| CN-101268046-A | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LTD (GB) | 2008-09-17 | — | — | CN | disclosed |
| EP-1928821-A1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
| WO-2007034325-A1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2007-03-29 | — | — | WO | disclosed |
| US-4221919-A | Antiinflammatory substituted phenylacetic acids | SPOFA, UNITED PHARMACEUTICAL WORKS (CS) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251164-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | GAA 3248/4885TSHR 104/4885TTR 3631/4885 |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | GAA 3248/4885TSHR 104/4885TTR 3631/4885 |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | GAA 3248/4885TSHR 104/4885TTR 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.